Is DRUG or RLAY more profitable?

Bright Minds Biosciences' return on equity of -20.58% beat Relay Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Bright Minds Biosciences N/A -20.58% -20.25% Relay Therapeutics N/A -43.94% -40.11%

Which has preferable valuation and earnings, DRUG or IRON?

Bright Minds Biosciences is trading at a lower price-to-earnings ratio than Disc Medicine, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bright Minds Biosciences N/A N/A -$8.74M -$2.44 N/A Disc Medicine N/A N/A -$212.18M -$6.62 N/A

Is DRUG or IRON more profitable?

Bright Minds Biosciences' return on equity of -20.58% beat Disc Medicine's return on equity. Company Net Margins Return on Equity Return on Assets Bright Minds Biosciences N/A -20.58% -20.25% Disc Medicine N/A -36.94% -33.88%

Which has stronger earnings and valuation, DRUG or KLRA?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bright Minds Biosciences N/A N/A -$8.74M -$2.44 N/A Kailera Therapeutics N/A N/A N/A N/A N/A

Is DRUG or KLRA more profitable?

Kailera Therapeutics' return on equity of 0.00% beat Bright Minds Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Bright Minds Biosciences N/A -20.58% -20.25% Kailera Therapeutics N/A N/A N/A

Is DRUG or IDYA more profitable?

IDEAYA Biosciences' return on equity of -14.24% beat Bright Minds Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Bright Minds Biosciences N/A -20.58% -20.25% IDEAYA Biosciences N/A -14.24% -13.09%

Bright Minds Biosciences (DRUG) Competitors

$60.95 0.00 (0.00%)

Closing price 06/12/2026 04:00 PM Eastern

Extended Trading

$60.63 -0.32 (-0.53%)

As of 06/12/2026 06:27 PM Eastern

Compare

DRUG vs. RLAY, IRON, KLRA, IDYA, and ALMS

Should you buy Bright Minds Biosciences stock or one of its competitors? MarketBeat compares Bright Minds Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Bright Minds Biosciences include Relay Therapeutics (RLAY), Disc Medicine (IRON), Kailera Therapeutics (KLRA), IDEAYA Biosciences (IDYA), and Alumis (ALMS). These companies are all part of the "pharmaceutical products" industry.

How does Bright Minds Biosciences compare to Relay Therapeutics?

Bright Minds Biosciences (NASDAQ:DRUG) and Relay Therapeutics (NASDAQ:RLAY) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, risk, dividends, analyst recommendations, institutional ownership and earnings.

Bright Minds Biosciences has a beta of -5.53, suggesting that its stock price is 653% less volatile than the broader market. Comparatively, Relay Therapeutics has a beta of 1.75, suggesting that its stock price is 75% more volatile than the broader market.

In the previous week, Relay Therapeutics had 3 more articles in the media than Bright Minds Biosciences. MarketBeat recorded 4 mentions for Relay Therapeutics and 1 mentions for Bright Minds Biosciences. Bright Minds Biosciences' average media sentiment score of 1.92 beat Relay Therapeutics' score of 1.10 indicating that Bright Minds Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Bright Minds Biosciences	Very Positive
Relay Therapeutics	Positive

Bright Minds Biosciences has higher earnings, but lower revenue than Relay Therapeutics. Bright Minds Biosciences is trading at a lower price-to-earnings ratio than Relay Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bright Minds Biosciences	N/A	N/A	-$8.74M	-$2.44	N/A
Relay Therapeutics	$15.35M	184.85	-$276.48M	-$1.57	N/A

Bright Minds Biosciences' return on equity of -20.58% beat Relay Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bright Minds Biosciences	N/A	-20.58%	-20.25%
Relay Therapeutics	N/A	-43.94%	-40.11%

Bright Minds Biosciences presently has a consensus target price of $143.83, suggesting a potential upside of 135.99%. Relay Therapeutics has a consensus target price of $23.30, suggesting a potential upside of 57.33%. Given Bright Minds Biosciences' higher probable upside, research analysts plainly believe Bright Minds Biosciences is more favorable than Relay Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bright Minds Biosciences	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86
Relay Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.00

40.5% of Bright Minds Biosciences shares are held by institutional investors. Comparatively, 97.0% of Relay Therapeutics shares are held by institutional investors. 42.7% of Bright Minds Biosciences shares are held by company insiders. Comparatively, 5.0% of Relay Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Relay Therapeutics beats Bright Minds Biosciences on 9 of the 15 factors compared between the two stocks.

How does Bright Minds Biosciences compare to Disc Medicine?

Bright Minds Biosciences (NASDAQ:DRUG) and Disc Medicine (NASDAQ:IRON) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, institutional ownership, media sentiment, earnings, profitability and dividends.

Bright Minds Biosciences has a beta of -5.53, suggesting that its stock price is 653% less volatile than the broader market. Comparatively, Disc Medicine has a beta of 0.93, suggesting that its stock price is 7% less volatile than the broader market.

40.5% of Bright Minds Biosciences shares are held by institutional investors. Comparatively, 83.7% of Disc Medicine shares are held by institutional investors. 42.7% of Bright Minds Biosciences shares are held by insiders. Comparatively, 3.8% of Disc Medicine shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Bright Minds Biosciences currently has a consensus price target of $143.83, suggesting a potential upside of 135.99%. Disc Medicine has a consensus price target of $105.30, suggesting a potential upside of 54.88%. Given Bright Minds Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Bright Minds Biosciences is more favorable than Disc Medicine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bright Minds Biosciences	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86
Disc Medicine	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

In the previous week, Disc Medicine had 19 more articles in the media than Bright Minds Biosciences. MarketBeat recorded 20 mentions for Disc Medicine and 1 mentions for Bright Minds Biosciences. Bright Minds Biosciences' average media sentiment score of 1.92 beat Disc Medicine's score of 0.80 indicating that Bright Minds Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Bright Minds Biosciences	Very Positive
Disc Medicine	Positive

Bright Minds Biosciences is trading at a lower price-to-earnings ratio than Disc Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bright Minds Biosciences	N/A	N/A	-$8.74M	-$2.44	N/A
Disc Medicine	N/A	N/A	-$212.18M	-$6.62	N/A

Bright Minds Biosciences' return on equity of -20.58% beat Disc Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bright Minds Biosciences	N/A	-20.58%	-20.25%
Disc Medicine	N/A	-36.94%	-33.88%

Summary

Bright Minds Biosciences beats Disc Medicine on 8 of the 13 factors compared between the two stocks.

How does Bright Minds Biosciences compare to Kailera Therapeutics?

Bright Minds Biosciences (NASDAQ:DRUG) and Kailera Therapeutics (NASDAQ:KLRA) are both pharmaceutical products companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, profitability, earnings, analyst recommendations, valuation, institutional ownership, media sentiment and risk.

Kailera Therapeutics' return on equity of 0.00% beat Bright Minds Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bright Minds Biosciences	N/A	-20.58%	-20.25%
Kailera Therapeutics	N/A	N/A	N/A

Bright Minds Biosciences currently has a consensus target price of $143.83, suggesting a potential upside of 135.99%. Kailera Therapeutics has a consensus target price of $42.75, suggesting a potential upside of 126.31%. Given Bright Minds Biosciences' higher probable upside, analysts clearly believe Bright Minds Biosciences is more favorable than Kailera Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bright Minds Biosciences	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86
Kailera Therapeutics	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	3.00

40.5% of Bright Minds Biosciences shares are owned by institutional investors. 42.7% of Bright Minds Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bright Minds Biosciences	N/A	N/A	-$8.74M	-$2.44	N/A
Kailera Therapeutics	N/A	N/A	N/A	N/A	N/A

In the previous week, Kailera Therapeutics had 1 more articles in the media than Bright Minds Biosciences. MarketBeat recorded 2 mentions for Kailera Therapeutics and 1 mentions for Bright Minds Biosciences. Bright Minds Biosciences' average media sentiment score of 1.92 beat Kailera Therapeutics' score of 1.27 indicating that Bright Minds Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Bright Minds Biosciences	Very Positive
Kailera Therapeutics	Positive

Summary

Bright Minds Biosciences and Kailera Therapeutics tied by winning 5 of the 10 factors compared between the two stocks.

How does Bright Minds Biosciences compare to IDEAYA Biosciences?

Bright Minds Biosciences (NASDAQ:DRUG) and IDEAYA Biosciences (NASDAQ:IDYA) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, earnings, media sentiment, risk, profitability, analyst recommendations and dividends.

IDEAYA Biosciences' return on equity of -14.24% beat Bright Minds Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bright Minds Biosciences	N/A	-20.58%	-20.25%
IDEAYA Biosciences	N/A	-14.24%	-13.09%

Bright Minds Biosciences has higher earnings, but lower revenue than IDEAYA Biosciences. Bright Minds Biosciences is trading at a lower price-to-earnings ratio than IDEAYA Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bright Minds Biosciences	N/A	N/A	-$8.74M	-$2.44	N/A
IDEAYA Biosciences	$218.71M	11.64	-$113.70M	-$1.60	N/A

40.5% of Bright Minds Biosciences shares are owned by institutional investors. Comparatively, 98.3% of IDEAYA Biosciences shares are owned by institutional investors. 42.7% of Bright Minds Biosciences shares are owned by insiders. Comparatively, 4.7% of IDEAYA Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Bright Minds Biosciences has a beta of -5.53, meaning that its share price is 653% less volatile than the broader market. Comparatively, IDEAYA Biosciences has a beta of -0.04, meaning that its share price is 104% less volatile than the broader market.

Bright Minds Biosciences currently has a consensus price target of $143.83, indicating a potential upside of 135.99%. IDEAYA Biosciences has a consensus price target of $50.69, indicating a potential upside of 74.91%. Given Bright Minds Biosciences' stronger consensus rating and higher probable upside, equities research analysts plainly believe Bright Minds Biosciences is more favorable than IDEAYA Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bright Minds Biosciences	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86
IDEAYA Biosciences	1 Sell rating(s)	1 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.82

In the previous week, IDEAYA Biosciences had 10 more articles in the media than Bright Minds Biosciences. MarketBeat recorded 11 mentions for IDEAYA Biosciences and 1 mentions for Bright Minds Biosciences. Bright Minds Biosciences' average media sentiment score of 1.92 beat IDEAYA Biosciences' score of 0.40 indicating that Bright Minds Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Bright Minds Biosciences	Very Positive
IDEAYA Biosciences	Neutral

Summary

IDEAYA Biosciences beats Bright Minds Biosciences on 9 of the 14 factors compared between the two stocks.

How does Bright Minds Biosciences compare to Alumis?

Bright Minds Biosciences (NASDAQ:DRUG) and Alumis (NASDAQ:ALMS) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, media sentiment, profitability, dividends, risk and institutional ownership.

In the previous week, Alumis had 2 more articles in the media than Bright Minds Biosciences. MarketBeat recorded 3 mentions for Alumis and 1 mentions for Bright Minds Biosciences. Bright Minds Biosciences' average media sentiment score of 1.92 beat Alumis' score of 0.63 indicating that Bright Minds Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Bright Minds Biosciences	Very Positive
Alumis	Positive

Bright Minds Biosciences has a net margin of 0.00% compared to Alumis' net margin of -2,825.70%. Bright Minds Biosciences' return on equity of -20.58% beat Alumis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bright Minds Biosciences	N/A	-20.58%	-20.25%
Alumis	-2,825.70%	-88.79%	-70.72%

Bright Minds Biosciences currently has a consensus target price of $143.83, suggesting a potential upside of 135.99%. Alumis has a consensus target price of $40.30, suggesting a potential upside of 66.87%. Given Bright Minds Biosciences' stronger consensus rating and higher probable upside, equities research analysts clearly believe Bright Minds Biosciences is more favorable than Alumis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bright Minds Biosciences	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86
Alumis	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83

Bright Minds Biosciences has a beta of -5.53, suggesting that its share price is 653% less volatile than the broader market. Comparatively, Alumis has a beta of -0.55, suggesting that its share price is 155% less volatile than the broader market.

40.5% of Bright Minds Biosciences shares are held by institutional investors. 42.7% of Bright Minds Biosciences shares are held by insiders. Comparatively, 33.7% of Alumis shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Bright Minds Biosciences has higher earnings, but lower revenue than Alumis. Bright Minds Biosciences is trading at a lower price-to-earnings ratio than Alumis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bright Minds Biosciences	N/A	N/A	-$8.74M	-$2.44	N/A
Alumis	$24.05M	128.02	-$243.32M	-$1.98	N/A

Summary

Bright Minds Biosciences beats Alumis on 9 of the 16 factors compared between the two stocks.

Get Bright Minds Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DRUG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DRUG vs. The Competition

Export

Metric	Bright Minds Biosciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$593.04M	$3.40B	$6.74B	$12.07B
Dividend Yield	N/A	2.25%	2.67%	5.67%
P/E Ratio	-24.98	19.82	24.21	24.42
Price / Sales	N/A	305.69	512.04	109.94
Price / Cash	N/A	53.61	27.48	37.92
Price / Book	7.32	8.32	10.66	6.83
Net Income	-$8.74M	$23.94M	$3.57B	$337.67M
7 Day Performance	-6.63%	1.84%	0.58%	1.17%
1 Month Performance	-21.32%	-0.04%	1.54%	3.16%
1 Year Performance	120.99%	44.82%	25.40%	30.58%

Bright Minds Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DRUG Bright Minds Biosciences	3.4077 of 5 stars	$60.95 flat	$143.83 +136.0%	+121.0%	$593.04M	N/A	N/A	N/A
RLAY Relay Therapeutics	3.2659 of 5 stars	$13.83 +1.2%	$23.30 +68.5%	+359.9%	$2.65B	$15.35M	N/A	330	Positive News Gap Down
IRON Disc Medicine	2.1741 of 5 stars	$68.07 +3.4%	$105.30 +54.7%	+26.6%	$2.59B	N/A	N/A	30	News Coverage Analyst Forecast
KLRA Kailera Therapeutics	4.8324 of 5 stars	$19.65 -0.3%	$42.75 +117.6%	N/A	$2.55B	N/A	N/A	145	Positive News Gap Up
IDYA IDEAYA Biosciences	2.788 of 5 stars	$29.00 -7.9%	$50.69 +74.8%	+30.7%	$2.54B	$218.71M	N/A	80	News Coverage Analyst Forecast Gap Down High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DRUG) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Bright Minds Biosciences (DRUG) Competitors

DRUG vs. RLAY, IRON, KLRA, IDYA, and ALMS

How does Bright Minds Biosciences compare to Relay Therapeutics?

Summary

How does Bright Minds Biosciences compare to Disc Medicine?

Summary

How does Bright Minds Biosciences compare to Kailera Therapeutics?

Summary

How does Bright Minds Biosciences compare to IDEAYA Biosciences?

Summary

How does Bright Minds Biosciences compare to Alumis?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DRUG vs. The Competition

Bright Minds Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Bright Minds Biosciences (DRUG) Competitors

DRUG vs. RLAY, IRON, KLRA, IDYA, and ALMS

How does Bright Minds Biosciences compare to Relay Therapeutics?

Which has more risk & volatility, DRUG or RLAY?

Does the media prefer DRUG or RLAY?

Which has higher earnings and valuation, DRUG or RLAY?

Is DRUG or RLAY more profitable?

Do analysts rate DRUG or RLAY?

Do insiders & institutionals hold more shares of DRUG or RLAY?

Summary

How does Bright Minds Biosciences compare to Disc Medicine?

Which has more risk and volatility, DRUG or IRON?

Do insiders and institutionals hold more shares of DRUG or IRON?

Do analysts recommend DRUG or IRON?

Does the media prefer DRUG or IRON?

Which has preferable valuation and earnings, DRUG or IRON?

Is DRUG or IRON more profitable?

Summary

How does Bright Minds Biosciences compare to Kailera Therapeutics?

Is DRUG or KLRA more profitable?

Do analysts prefer DRUG or KLRA?

Do insiders & institutionals hold more shares of DRUG or KLRA?

Which has stronger earnings and valuation, DRUG or KLRA?

Does the media favor DRUG or KLRA?

Summary

How does Bright Minds Biosciences compare to IDEAYA Biosciences?

Is DRUG or IDYA more profitable?

Which has higher earnings and valuation, DRUG or IDYA?

Do insiders & institutionals have more ownership in DRUG or IDYA?

Which has more risk & volatility, DRUG or IDYA?

Do analysts rate DRUG or IDYA?

Does the media prefer DRUG or IDYA?

Summary

How does Bright Minds Biosciences compare to Alumis?

Does the media refer more to DRUG or ALMS?

Is DRUG or ALMS more profitable?

Do analysts rate DRUG or ALMS?

Which has more risk & volatility, DRUG or ALMS?

Do insiders & institutionals hold more shares of DRUG or ALMS?

Which has preferable valuation and earnings, DRUG or ALMS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DRUG vs. The Competition

Bright Minds Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools